Zydus Cadila has received the tentative approval from the USFDA to market Deferasirox Tablets for Oral Suspension (Exjade Tablets) in the strengths of 125 mg, 250 mg and 500 mg. It is used to treat ongoing high levels of iron in the body caused by multiple blood transfusions. It is also used to treat high levels of iron in people with a certain blood disorder who do not require blood transfusions (non-transfusion-dependent thalassemia). It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad. The estimated sale for Deferasirox Tablets is $ 150.3 million (Source: IMS Health, IMS National Sales Perspective Audit, MAT May 2018, extracted June 2018.)
In line with this, the group now has 202 approvals and has so far filed over 330 ANDAs since the commencement ofthe filing process in FY 2003—04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.381.7 as compared to the previous close of Rs. 386.25. The total number of shares traded during the day was 45267 in over 789 trades.
The stock hit an intraday high of Rs. 391 and intraday low of 380.1. The net turnover during the day was Rs. 17509231.